MediWound Ltd. (MDWD) Upgraded to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of MediWound Ltd. (NASDAQ:MDWD) from a hold rating to a buy rating in a report published on Wednesday morning. They currently have $5.75 target price on the biopharmaceutical company’s stock.
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
A number of other brokerages have also commented on MDWD. Jefferies Group LLC set a $10.00 price target on MediWound and gave the stock a buy rating in a report on Friday, August 25th. SunTrust Banks, Inc. reiterated a buy rating on shares of MediWound in a report on Monday, June 26th. Cowen and Company initiated coverage on MediWound in a report on Thursday, September 28th. They set an outperform rating and a $9.00 price target on the stock. ValuEngine lowered MediWound from a sell rating to a strong sell rating in a report on Friday, September 22nd. Finally, Oppenheimer Holdings, Inc. reiterated a buy rating and set a $10.00 price target on shares of MediWound in a report on Monday, September 18th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $9.15.
MediWound (NASDAQ MDWD) opened at 5.15 on Wednesday. MediWound has a 52-week low of $4.25 and a 52-week high of $8.25. The firm’s 50 day moving average price is $5.73 and its 200 day moving average price is $6.43. The firm’s market cap is $113.06 million.
MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The company had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. During the same quarter in the prior year, the business earned ($0.34) EPS. The firm’s revenue for the quarter was up 93.8% compared to the same quarter last year. Equities research analysts anticipate that MediWound will post ($0.76) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in MDWD. Migdal Insurance & Financial Holdings Ltd. increased its position in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after buying an additional 342,165 shares during the last quarter. Wellington Management Group LLP increased its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock worth $14,241,000 after buying an additional 213,745 shares during the last quarter. Wells Fargo & Company MN increased its position in MediWound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 12,522 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after purchasing an additional 1,300 shares in the last quarter. 19.55% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.